Potential 100 bagger Biotech missed by the market, page-877

Biogen’s Market Cap jumped by 20 billion in response to their drug getting FDA approval- a drug which failed to produce a beneficial response to Alzheimer’s. And was forecast to have 7 billion dollars in annual sales.
NSB’s EmtinB looks highly promising and upon any clinical proof of concept will be snapped up by a big pharmaceutical company. NSB doesn’t have spend years trying to get FDA approval as it will be bought out before this step.
This week’s market response to Biogen shows that a potential Alzheimer’s drug is worth billions of dollars.
NSB’s buyout price will be somewhere north of a billion dollars. Only time will tell what the final numeral at the front will be.